Trump/Cook, Nissan weakness, more tariffs and gold - what’s moving markets
Mark Leonard Singleton, Senior Vice President and Chief Financial Officer of Bioventus Inc. (NASDAQ:BVS), recently sold 6,498 shares of the company’s Class A common stock. The shares were sold on February 18, 2025, at an average price of $10.19 per share, amounting to a total transaction value of $66,214. The transaction occurred as Bioventus stock has shown remarkable strength, delivering a 126% return over the past year, according to InvestingPro data.
This sale was executed as part of a pre-established 10b5-1 trading plan, which Singleton adopted on March 15, 2024. The transaction was part of a broader trade involving multiple employees of Bioventus, with the sale prices ranging from $9.74 to $10.61 per share. Following this transaction, Singleton retains direct ownership of 118,817 shares in the company. While currently unprofitable, InvestingPro analysis indicates the company is expected to return to profitability this year, with analysts setting price targets between $13 and $17. For deeper insights into BVS’s valuation and growth prospects, access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.
In other recent news, Bioventus Inc has completed the divestiture of its Advanced Rehab business to Accelmed Partners, a move that aligns with the company’s projected timeline for the end of 2024 to early 2025. This segment, which includes devices designed to support recovery of leg or hand function, was originally acquired through Bioventus’ purchase of Bioness in 2021. The divestiture is seen as a strategic decision, allowing Bioventus to sharpen its focus on its remaining portfolio, particularly in areas like Ultrasonics and international growth. Canaccord Genuity has reaffirmed its Buy rating and maintained a $15.00 price target for Bioventus, viewing the sale as a positive development. The firm anticipates that this move will potentially improve margins and reduce debt for Bioventus. While Canaccord Genuity has not yet adjusted its financial model or estimates to reflect this transaction, it remains optimistic about the company’s future prospects. The divestiture is expected to free up resources for Bioventus to concentrate on growth areas, including its peripheral nerve stimulation business, which remains part of its Pain Treatments portfolio.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.